In about 50% of melanoma cells resistant MAPK-pathway inhibitors, such as Vem, the Rho/MRTF pathway is upregulated upon prolonged drug exposure (Ho et al., 2012; Vogel et al., 2015; Islam et al., 2017; Misek et al., 2020; Orgaz et al., 2020; Appleton et al., 2021; Kim et al., 2021; Foda and Neubig, 2023; Murali et al., 2024). This evidence concerns the gene RHO and melanoma.